Novavax says CDC advisors in favor of added COVID vaccine dose for 65 and older

Novavax announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted in favor, 11 to 1 with 1 abstain, to recommend that individuals aged 65 and older should receive an additional dose of 2023-2024 Formula COVID-19 vaccine four months since receipt of the last dose. ACIP’s recommendation will now be considered for adoption by the CDC. Doses of the Novavax COVID-19 Vaccine, Adjuvanted 2023-2024 Formula, or NVX-CoV2601, are available at major retail pharmacies nationwide and can be ordered through one of the company’s distribution partners for physician use in the non-retail setting, Novavax stated.